Strategic partnership ReiThera actively engages in collaborations with industry players and academic bodies (e.g., Trellis Research Group, SillaJen, Sabin Vaccine Institute, AAVantgarde), indicating openness to joint development and contract opportunities for scalable AAV, AdV, and gene therapy manufacturing.

AAV manufacturing focus With extensive GMP production experience in AAV, Lentivirus, AdV, and multi-vector platforms, ReiThera is a strong partner for CDMO projects requiring viral-vector process development, scale-up, and fill-finish capabilities.

Expansion-ready capacity Having scalable bioreactors from 50L to 2000L and fixed-bed systems, plus a GMP filling suite and QC labs, ReiThera can accommodate mid-stage to late-stage clinical manufacturing and potential rightsizing for client programs.

Clinical gene therapy expertise Strategic collaborations on SJ-600 series and participation in ESGCT discussions signal expertise in genetic vaccines and advanced therapies, presenting opportunities for co-development, technology transfer, and manufacturing partnerships for novel constructs.

Geographic and network reach Headquartered in Rome with global collaboration activity (e.g., Rwanda, Sabin Institute, Trellis), ReiThera offers potential for regional manufacturing footprints, regulatory support, and international supply chain partnerships to accelerate clinical programs.